• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Innovation Pharmaceuticals Inc.

Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate
July 22, 2022
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium
June 28, 2022
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers
June 23, 2022
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology
June 15, 2022
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin
March 15, 2022
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases
March 07, 2022
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022
December 07, 2021
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals Provides Brilacidin Program Update
November 18, 2021
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin's Potential Inclusion in Government-Sponsored COVID-19 Trials
November 12, 2021
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals Announces Topline Results from Phase 2 Clinical Trial of Brilacidin for COVID-19
November 11, 2021
From Innovation Pharmaceuticals Inc.
Via AccessWire
Topics Death
Tickers IPIX
Database Lock Completed for Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19
November 03, 2021
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals' COVID-19 Clinical Trial Topline Results Anticipated to Be Reported the Week of November 8th
October 25, 2021
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin's Broad-Spectrum Antiviral Properties
September 23, 2021
From Innovation Pharmaceuticals Inc.
Via AccessWire
Tickers IPIX
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap